Risk Stratification of Patients With Suspected COVID-19 Presenting to the ED
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University Hospital, Tours
- Enrollment
- 7,876
- Locations
- 1
- Primary Endpoint
- Mortality
Study Overview
Brief Summary
Descriptive study of patients with suspected COVID-19 upon ED arrival of European hospitals between March 09 and April 08 2020.
Justification:
Detailed Description
Descriptive study of patients with suspected COVID-19 upon ED arrival of European hospitals between March 09 and April 08 2020.
Justification:
Over the past 3 months, the world has faced a novel infection disease outbreak, due to a novel coronavirus, the severe acute respiratory syndrome coronavirus (SARS-CoV2), with a massive impact on healthcare resource.
In Europe, numbers of confirmed cases continue to rise. Europe is currently one of the regions with the highest number of Covid-19 cases and deaths due to this emergent diseases.
Most COVID-19 infected patients present with mild to moderate acute respiratory symptoms, including cough, fever, dyspnea and pneumonia. About 20% will present with severe or critical manifestations of the disease, including pneumonia, respiratory failure and acute respiratory distress syndrome (ARDS).
Study Design
- Study Type
- Observational
- Observational Model
- Other
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adult patients (>= 18 years old) attending the ED with a clinical suspicion of COVID-19 based on the presence of the following criteria
- •Fever >= 38 °C
- •respiratory symptoms (dyspnea, cough, expectorations)
- •any other symptoms suggestive of COVID-19 including digestive signs (diarrhea, anosmia...)
Exclusion Criteria
- •No insurance
- •patients less than 18 years
Outcomes
Primary Outcomes
Mortality
Time Frame: through study completion, an average of 30 days
Mortality during hospital management
Secondary Outcomes
No secondary outcomes reported
Investigators
Saïd LARIBI
Principal Investigator
University Hospital, Tours